References
- Kleihues P, Cavanee WK. World Health Organization: Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Barnes L, Eveson JW, Sidransky D (Eds). IARC Press, Lyon, France (2000).
- Berger M, Wilson C. (Eds). The Gliomas. WB Saunders, PA, USA (1999).
- Anderson NL, Anderson NG. The human plasma proteome history, character, and diagnostic prospects. Mol. Cell. Proteomics1, 845–867 (2002).
- Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis19(11), 1853–1861 (1998).
- Blackstock WP, Weir MP. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol.17(3), 121–127 (1999).
- Steel LF, Habb BB, Hanash SM. Methods of comparative proteomic profiling for disease diagnostics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.815(1–2), 275–284 (2005).
- Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik26(3), 231–243 (1975).
- O’Farrell PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem.250(10), 4007–4021 (1975).
- Anderson L, Anderson NG. High resolution two-dimensional electrophoresis of human plasma proteins. Proc. Natl Acad. Sci. USA74(12), 5421–5425 (1977).
- Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis18(11), 2071–2077 (1997).
- Nagele E, Vollmer M, Horth P, Vad C. 2D-LC/MS techniques for the identification of proteins in highly complex mixtures. Expert Rev. Proteomics1(1), 37–46 (2004).
- Washburn MP, Wolters D, Yates JR III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol.19(3), 242–247 (2001).
- Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol.17(10), 994–999 (1999).
- Patterson SD, Aebersold R. Mass spectrometric approaches for the identification of gel-separated proteins. Electrophoresis16(10), 1791–1814 (1995).
- Chen G, Pramanik BN. Application of LC/MS to proteomics studies: current status and future prospects. Drug Discov. Today14(9–10), 465–471 (2009).
- Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet359, 572–575 (2002).
- Powell K. Proteomics delivers on promise of cancer biomarkers. Nat. Med.9, 980 (2003).
- Diamandis EP. Point: proteomics patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem.48(8), 1272–1275 (2003).
- Haab BB. Antibody arrays in cancer research. Mol. Cell. Proteomics4, 377–383 (2005).
- Angenendt P, Kreutzberger J, Glokler J, Hoheisal JD. Generation of high density protein microarrays by cell-free in situ expression of unpurified PCR products. Mol. Cell. Proteomics5(9), 1658–1666 (2006).
- Kim BK, Lee JW, Park PJ et al. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res.11(2), 22 (2009).
- Stupp R, Reni M, Gatta G, Mazza E, Vecht C. Anaplastic astrocytoma in adults. Crit. Rev. Oncol. Hematol.63(1), 72–80 (2007).
- Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist11(2), 152–164 (2006).
- Petrik V, Saadoun S, Loosemore A et al. Serum α2-hs glycoprotein predicts survival in patients with glioblastoma. Clin. Chem.54(4), 713–722 (2008).
- Zhang H, Wu G, Tu H et al. Discovery of serum biomarkers in astrocytoma by SELDI–TOF MS and proteinchip technology. J. Neurooncol.84(3), 315–332 (2007).
- Azok J, Guccione S, Lim M et al. The use of magnetic resonance imaging to guide the analysis of serum proteomic patterns in glioblastoma multiforme. Proc. Intl. Soc. Mag. Reson. Med.11, 220 (2004).
- Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res.62(15), 4364–4368 (2002).
- Reddy PS, Umesh S, Thota B et al. PBEF1/NAmPRTase/Visfatin a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol. Ther.7(5), 663–668 (2008).
- Hzecka A, Hzecki M. APRIL is increased in serum of patients with brain glioblastoma multiforme. Eur. Cytokine Netw.17(4), 276–280 (2006).
- Jung CS, Foerch C, Schänzer A et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain130(12), 3336–3341 (2007).
- Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol. Ther.2(3), 242–247 (2003).
- Hormigo A, Gu B, Karimi S et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin. Cancer Res.12(19), 5698–5704 (2006).
- Iwadate Y, Hayama M, Adachi A et al. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res.28(1B), 415–418 (2008).
- Lin Y, Jiang T, Zhou K et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro. Oncol. DOI:10.1215/15228517-2008-114 (2009) (Epub ahead of print).
- Quaranta M, Divella R, Daniele A et al. Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. Tumori93(3), 275–280 (2007).
- Fukuda ME, Iwadate Y, Machida T et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res.65(12), 5190–5194 (2005).
- Nano R, Capelli E, Argentina F, Facoetti A, Gerzeli G. Evaluation of serum levels of cytokines and intercellular adhesion molecule-1 (ICAM-1) in astrocytic tumours. Cell. Mol. Biol.49(4), 525–528 (2003).
- Ammirati M, Rao S, Granger G et al. Detection of TNF inhibitors (soluble receptors) in the sera and tumor cyst fluid of patients with malignant astrocytomas of the brain. Front. Biosci.6, B17–B24 (2001).
- Zheng PP, Hop WC, Sillevis Smitt PA et al. Low-molecularweight caldesmon as a potential serum marker for glioma. Clin. Cancer Res.11(12), 4388–4392 (2005).
- Wrensch M, Wiencke JK, Wiemels J et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res.66(8), 4531–4541 (2006).
- Guccione S, Yang Y, Chia Y et al. Identification of serum markers of glioblastoma multiforme patients using image-guided genomic and proteomic analysis. J. Clin. Oncol.24(18 Suppl.), 20008 (2006).
- Todaro L, Christiansen S, Varela et al. Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J. Neurooncol.83(2), 135–144 (2007).
Websites
- Mascot www.matrixscience.com
- PepIdent www.unb.br/cbsp/paginiciais/pepident.htm
- ProFound www.unb.br/cbsp/paginiciais/profound.htm
- Genome fingerprint scanning http://gfs.unc.edu/cgi-bin/WebObjects/GFSWeb